Septerna, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna CFO Sells Shares
Gil M Labrucherie, Chief Financial Officer of Septerna, Inc., sold 20,000 shares of common stock on November 16, 2026.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna CEO Sells Shares
Jeffrey Finer, Chief Executive Officer and a Director of Septerna, Inc., sold 18,500 shares of common stock on November 12, 2026.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna Director Sells Shares
Alan Ezekowitz, a Director of Septerna, Inc., sold 81,820 shares of common stock on November 11, 2026.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna COO Sells Shares
Elizabeth Bhatt, President and COO of Septerna, Inc., sold 4,000 shares of common stock on October 15, 2026.
NASDAQ
SEPN
Septerna, INCRajiv Patni, Chief Medical Officer of Septerna, Inc., received 275,000 shares of common stock on September 8, 2026.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna Executive Sells Shares
Daniel D. Long, SVP, Drug Discovery of Septerna, Inc., sold 3,333 shares of common stock on September 1, 2026 for $37.83 per share.
NASDAQ
SEPN
Septerna, INCThird Rock Ventures V, L.P. and 5 others reported changes in beneficial ownership of Septerna, Inc. common stock on August 12, 2026.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna Insider Sells Shares
Ra Capital Management, L.P. and 4 others reported changes in beneficial ownership of Septerna, Inc. common stock on August 12, 2026.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna COO Sells Shares
Elizabeth Bhatt, President and COO of Septerna, Inc., sold 25,000 shares of common stock on August 11, 2026 for $44.00 per share.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna Executive Sells Shares
Daniel D. Long, SVP, Drug Discovery of Septerna, Inc., sold 3,334 shares of common stock on August 3, 2026.
NASDAQ
SEPN
Septerna, INCForm 4: Septerna COO Sells Shares
Elizabeth Bhatt, President and COO of Septerna, Inc., sold 4,000 shares of common stock on July 15, 2026 for $33.99 per share.
NASDAQ
SEPN
Septerna, INCSepterna Inc. SVP Daniel D. Long sold company stock valued at over $100,000 through a pre-arranged 10b5-1 plan, while also acquiring shares via stock options.
NASDAQ
SEPN
Septerna, INCRA Capital Management, L.P. and affiliated entities have reported the acquisition of a stock option for 15,000 shares of Septerna, Inc. (SEPN) common stock.
NASDAQ
SEPN
Septerna, INCSepterna Inc. Chief People Officer Samira Shaikhly sold 2,178 shares of common stock for $6.81 each, as part of a pre-arranged 10b5-1 trading plan.
NASDAQ
SEPN
Septerna, INCSepterna, Inc. Director Abraham Bassan acquired 15,000 stock options with an exercise price of $37.34, vesting under specific service conditions.
NASDAQ
SEPN
Septerna, INCSepterna Inc. director Shalini Sharp has been granted 15,000 stock options with an exercise price of $37.34, vesting under specific service conditions.
NASDAQ
SEPN
Septerna, INCSepterna, Inc. director Bernard Coulie has acquired 15,000 stock options, with vesting tied to service and the company's next annual meeting.
NASDAQ
SEPN
Septerna, INCSepterna, Inc. director Jeffrey K. Tong acquired 15,000 stock options with an exercise price of $37.34, vesting in full by June 26, 2027, or the next annual meeting.
NASDAQ
SEPN
Septerna, INCSepterna, Inc. reports a Form 4 filing detailing stock option grants to Director Keith Michael Gottesdiener.
NASDAQ
SEPN
Septerna, INCSepterna, Inc. director Alan Ezekowitz was granted 15,000 stock options with an exercise price of $37.34, vesting in full by June 26, 2027 or the next annual meeting.
NASDAQ
SEPN
Septerna, INCSepterna, Inc. Director Jake Simson acquired stock options, with the underlying shares held for the benefit of RA Capital Management funds.
NASDAQ
SEPN
Septerna, INCSepterna, Inc. SVP of Drug Discovery, Daniel D. Long, engaged in a series of stock transactions, acquiring shares through an employee stock purchase plan and options, while also selling a portion of his holdings.
NASDAQ
SEPN
Septerna, INCChief People Officer Samira Shaikhly exercised options to acquire and subsequently sold 6,250 shares of Septerna, Inc. common stock.
NASDAQ
SEPN
Septerna, INCChief People Officer Samira Shaikhly exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
SEPN
Septerna, INCChief People Officer Samira Shaikhly exercised options for 11,798 shares of Septerna, Inc. and subsequently sold them under a Rule 10b5-1 plan.
NASDAQ
SEPN
Septerna, INCSepterna President and COO Elizabeth Bhatt exercised stock options and sold shares under a pre-arranged 10b5-1 plan.
NASDAQ
SEPN
Septerna, INCSepterna's Chief People Officer, Samira Shaikhly, exercised stock options and simultaneously sold an equal number of shares totaling over $1.98 million under a pre-arranged 10b5-1 plan.
NASDAQ
SEPN
Septerna, INCSepterna, Inc.'s SVP of Drug Discovery, Daniel D. Long, was granted 80,000 stock options with an exercise price of $25.41, vesting over 48 months.
NASDAQ
SEPN
Septerna, INCSepterna's SVP of Biological Sciences, Uwe Klein, was granted 80,000 stock options with a vesting schedule tied to continuous service.
NASDAQ
SEPN
Septerna, INCSepterna's Chief People Officer, Samira Shaikhly, was granted 80,000 stock options with an exercise price of $25.41, vesting over approximately four years.